Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer

Inclusion Criteria: 1. signed and written informed consent 2. age ≥ 18 years 3. patients eligible for interval cytoreductive surgery 1. histological proven FIGO stage III primary high grade serous ovarian, fallopian tube, or extra-ovarian cancer 2. when only cytology is performed to confirm the diagnosis ovarian carcinoma, immunohistochemistry should be performed including keratin 7, keratin 20, p53, PAX8 3. neo-adjuvant chemotherapy consists of (at least) 3 courses of carboplatin/paclitaxel 4. following 2 cycles of chemotherapy no progression should occur 4. treated with optimal or complete interval cytoreductive surgery 5. fit for major surgery, WHO performance status 0-2 6. adequate bone marrow function (hemoglobin level \>5.5 mmol/L; leukocytes \>3 x 109/L; platelets \>100 x 109 /L) 7. adequate hepatic function (ALT, AST and bilirubin \<2.5 times upper limit of normal) 8. adequate renal function (creatinine clearance ≥ 60 ml/min using Cockcroft-Gault formula or 24-hour measurement or ml/min/1,73 m2 using MDRD or CKD-EPI) 9. able to understand the patient information Exclusion Criteria: 1. history of previous malignancy treated with chemotherapy 2. opting for fertility-sparing surgery